A New Weight Loss Pill You Don't Have to Take on an Empty Stomach

If you've been following the world of weight loss treatments, you'll know that the last few years have been transformative. Injections like Wegovy and Mounjaro have changed the conversation around obesity, helping millions of people achieve meaningful weight loss for the first time. But not everyone wants — or is able — to use a weekly injection. Many people would prefer a simple daily tablet.

That's where orforglipron comes in. Developed by Eli Lilly, orforglipron is a once-daily weight loss pill currently in late-stage clinical trials, with UK availability potentially as early as 2026. If approved, it would be the first pill of its kind specifically developed for weight loss — and unlike existing oral options, you can take it at any time of day without worrying about food or water.

Here's everything we know so far.

How Does Orforglipron Work?

To understand orforglipron, it helps to know a little about how your body controls hunger. After you eat, your gut releases a hormone called GLP-1 (glucagon-like peptide-1). This hormone sends signals to your brain that you're full, slows down how quickly food leaves your stomach, and helps regulate your blood sugar levels. In people with obesity, these signals don't always work as effectively as they should.

Drugs like semaglutide (the active ingredient in Wegovy and Ozempic) work by mimicking this GLP-1 hormone. Orforglipron does the same thing — it activates the GLP-1 receptor in your brain and gut, helping to reduce your appetite, make you feel satisfied sooner, and lower your overall food intake.

The key difference is in how the drug is made. Semaglutide is a peptide, which means it's a modified version of the natural hormone itself. Because peptides are fragile and easily broken down by stomach acid, current oral semaglutide (sold as Rybelsus) comes with strict dosing instructions: you must take it first thing in the morning on a completely empty stomach, swallow it with no more than a sip of water, and then wait at least 30 minutes before eating, drinking, or taking any other medication.

Orforglipron is different. It's a small-molecule drug — not a peptide — which means it's far more resistant to being broken down in your digestive system. The practical benefit for you is significant: orforglipron can be taken at any time of day, with or without food, and with no restrictions on water intake. For many people, that convenience could make a real difference in sticking with treatment long-term.

What Do the Clinical Trials Show?

Orforglipron has been tested in several large-scale clinical trials, and the results have been published in some of the world's most respected medical journals.

Weight Loss in People Without Diabetes (ATTAIN-1)

The largest trial in people without diabetes is called ATTAIN-1, published in the New England Journal of Medicine in September 2025. It involved over 3,100 adults with obesity (or who were overweight with a weight-related health condition) across multiple countries. Participants were randomly assigned to take orforglipron at one of three doses — 6 mg, 12 mg, or 36 mg — or a placebo, once daily for 72 weeks (about a year and a half).

The results at 72 weeks showed:

- 6 mg dose: average weight loss of 7.5%

- 12 mg dose: average weight loss of 8.4%

- 36 mg dose: average weight loss of 11.2%

- Placebo: average weight loss of 2.1%

To put that into perspective, for someone weighing 15 stone (95 kg), the highest dose would translate to a loss of roughly 1.5 stone (about 10.6 kg) over 72 weeks.

Among those on the highest dose, over half (54.6%) lost at least 10% of their body weight, more than a third (36%) lost at least 15%, and nearly one in five (18.4%) lost 20% or more. For participants who took every dose as directed throughout the trial, the average weight loss on the highest dose was even higher — around 12.4%, or approximately 27 lbs (just over 12 kg).

Weight Loss in People With Type 2 Diabetes (ATTAIN-2)

A second major trial, ATTAIN-2, looked specifically at people who had both obesity and type 2 diabetes. This is important because weight loss can be harder to achieve when you have diabetes. The results, presented at Obesity Week in November 2025, showed that participants on the highest dose lost an average of 10.5% of their body weight (about 23 lbs) over 72 weeks, compared with just 2.2% on placebo. Blood sugar levels also improved significantly, with HbA1c (a key measure of long-term blood sugar control) dropping by up to 1.8%.

Maintaining Weight After Switching From Injections

One particularly interesting trial, called ATTAIN-MAINTAIN, looked at whether people who had already lost weight on injectable treatments (Wegovy or Zepbound) could maintain that weight loss by switching to orforglipron tablets. The results, announced in December 2025, were encouraging: participants who switched from Wegovy to orforglipron maintained their weight loss with only a very small difference — an average of just 2 lbs. This suggests that orforglipron could be a practical option for people who want to move away from injections after their initial weight loss phase.

What About Side Effects?

As with all GLP-1 based treatments, the most common side effects of orforglipron are digestive. In the ATTAIN-1 trial, the side effects most frequently reported were:

- Nausea — the most common, particularly in the first few weeks as the dose is gradually increased

- Diarrhoea

- Vomiting

- Constipation

These side effects were generally mild to moderate and tended to ease over time as the body adjusted to the medication. To minimise these effects, the dose is increased gradually — patients start at 1 mg and step up over several weeks to their final dose.

In the trial, between 5% and 10% of participants taking orforglipron stopped treatment because of side effects, compared with about 3% on placebo. Importantly, no serious liver safety concerns were identified across any of the trials, which is reassuring given that liver health is closely monitored with obesity treatments.

If you've taken Wegovy, Mounjaro, or Ozempic before, the side effect profile will feel familiar. The digestive symptoms are a class effect of GLP-1 drugs and are not unique to orforglipron.

Are There Additional Health Benefits Beyond Weight Loss?

Yes — and this is an important part of the picture. Obesity is not just about body weight; it significantly increases the risk of heart disease, stroke, and type 2 diabetes. In the ATTAIN-1 trial, orforglipron showed meaningful improvements in several markers of cardiovascular risk:

- Waist circumference was significantly reduced

- Blood pressure (systolic) improved

- Triglycerides (a type of blood fat linked to heart disease) decreased

- Non-HDL cholesterol (sometimes called "bad cholesterol") was lowered

These improvements were observed even at the lower doses and are clinically significant — meaning they're large enough to make a real difference to your long-term health, not just numbers on a chart. Researchers noted that these cardiometabolic benefits were comparable to those seen with injectable semaglutide, even though the overall weight loss with orforglipron was somewhat more modest.

There are no completed cardiovascular outcomes trials for orforglipron yet (the kind of large, long-term studies that directly measure whether a drug reduces heart attacks and strokes), so this is something to watch for in the future.

When Will Orforglipron Be Available in the UK?

This is the question many people are asking, and it's important to be clear about where things stand. Eli Lilly submitted orforglipron for approval to the US Food and Drug Administration (FDA) in December 2025, but this does not mean it is approved or available in the UK. The UK has its own regulatory process through the MHRA (Medicines and Healthcare products Regulatory Agency), and drugs must also be assessed by NICE (the National Institute for Health and Care Excellence) before they can be routinely prescribed on the NHS.

The good news is that NICE has already created a provisional stakeholder list for orforglipron for managing overweight and obesity, which is an encouraging early signal. Eli Lilly has publicly stated that the UK will be among the first countries to receive the drug, and UK obesity experts have suggested a launch in 2026 is realistic — though this remains subject to the regulatory process.

Until orforglipron is officially licensed in the UK, it cannot be legally prescribed or dispensed here. We would strongly advise against purchasing any unlicensed weight loss medications from overseas websites, as these products are unregulated and may be unsafe.